Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil dose comparison for bleeding control during lumbar fusion surgery
IRCT20200217046523N12Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of remifentanil in Lumbar Spinal Disease (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Blood pressure and Bleeding. Started Apr 2021; status: completed.
02
Drugs
remifentanil
03
Conditions
Lumbar Spinal Disease
Beyond the preview
Go deeper on IRCT20200217046523N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046523N12.